Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity

Anneline S. J. M. te Riele1,2, Cynthia A. James3, Hugh Calkins3 and Adalena Tsatsopoulou4*

1 Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, 2 Netherlands Heart Institute, Utrecht, Netherlands, 3 Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States, 4 Unit of Inherited and Rare Cardiovascular Diseases, Onassis Cardiac Surgery Center, Athens, Greece

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by fibrofatty infiltration of predominantly the right ventricular (RV) myocardium. Affected patients typically present as young adults with hemodynamically stable ventricular tachycardia, although pediatric cases are increasingly recognized. These young subjects often have a more severe phenotype with a high risk of sudden cardiac death (SCD) and progression toward heart failure. Diagnosis of ARVC is made by combining multiple sources of information as prescribed by the consensus-based Task Force Criteria. The description of Naxos disease, a fully penetrant autosomal recessive disorder that is associated with ARVC and a cutaneous phenotype of palmoplantar keratoderma and wooly hair facilitated the identification of the genetic cause of ARVC. At present, approximately 60% of patients are found to carry a pathogenic variant in one of five genes associated with the cardiac desmosome. The incomplete penetrance and variable expressivity of these variants however implies an important role for environmental factors, of which participation in endurance exercise is a strong risk factor. Since there currently is no definite cure for ARVC, disease management is directed toward symptom reduction, delay of disease progression, and prevention of SCD. This clinically focused review describes the spectrum of ARVC among children and adolescents, the genetic architecture underlying this disease, the cardio-cutaneous syndromes that led to its identification, and current diagnostic and therapeutic strategies in pediatric ARVC subjects.

Keywords: arrhythmogenic (right ventricular) cardiomyopathy, natural history, management, children, adolescent, pediatric, naxos disease

INTRODUCTION

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition of the heart and is part of the phenotypic spectrum of arrhythmogenic cardiomyopathies (ACM) that includes right-dominant (ARVC), left-dominant (ALVC) and biventricular arrhythmogenic cardiomyopathy (Figure 1) (1, 2). Our manuscript focuses on the right-dominant subform of pediatric ACM (i.e.,
ARVC); a description of left-dominant and biventricular ACM in pediatric patients can be found in the same issue of this journal (reference). ARVC is characterized by potentially severe ventricular arrhythmias and structural alterations of the ventricular myocardium, which are identified by macro- and microscopic pathological examination and/or abnormal cardiac imaging (1). While right ventricular (RV) structural abnormalities have been predominantly reported, advanced imaging techniques reveal increased incidence of left ventricular (LV) or biventricular involvement (3–5). A sudden death that occurred during exercise in a young doctor, who was previously noted to have episodes of sustained ventricular tachycardia (VT) of RV origin, was the “case 0” of the fundamental report of ARVC as a cause of juvenile sudden death (6, 7). Indeed, although the estimated prevalence of ARVC in the general population is only 1:5,000, it represents one of the most common causes of juvenile sudden death (8).

Since the initial disease description by Marcus and colleagues in 1982, most studied ARVC cohorts constituted mainly of adults (3). Arrhythmia-related episodes characterize affected patients, who commonly present at late adolescence or young adulthood. In subsequent years, familial occurrence of ARVC was recognized (9, 10), and pediatric cases were increasingly reported. These young patients often present with a high risk of severe ventricular arrhythmias or sudden cardiac death (11), underscoring the need for early disease detection. Nonetheless, reduced penetrance and variable expressivity in familial ARVC, complicated linkage studies during the early genotyping attempts (7). A breakthrough came with the identification of Naxos syndrome, a fully penetrant autosomal recessive disorder associating ARVC with a cutaneous phenotype of palmoplantar keratoderma and wooly hair that characterizes the patient from infancy. A pathogenic variant in the desmosomal protein junctional plakoglobin (JUP) was identified in Naxos disease and was the first causative gene for ARVC (12). Subsequently, pathogenic variants in other desmosomal proteins were related to ARVC. As a result, ARVC is currently considered a heritable desmosomal disorder and more than 60% of probands are now found to harbor a pathogenic desmosomal variant. Yet, non-desmosomal genes are increasingly identified among those with biventricular or left-dominant disease (13).

Although disease evolution and prognosis have been studied in large cohorts of index patients and family members (14), the question of when and how the disease manifests in children has not yet been elucidated. Few cohorts and sporadic cases of children with ARVC have been reported. A systematic follow-up of asymptomatic children carrying a pathogenic genetic variant will provide important information on disease initiation and uncover the earliest signs on how ARVC evolves during childhood.

This clinically focused review describes the spectrum of ARVC among children and adolescents, the genetic architecture underlying this disease, and the current diagnostic and therapeutic strategies in pediatric ARVC subjects.

**DIAGNOSIS**

The diagnosis of ARVC may be challenging, as no single modality is sufficiently sensitive or specific to serve as the gold standard for ARVC diagnosis. As such, multiple sources of diagnostic information are combined in a complex set of criteria determined by a Task Force in 1994, which were subsequently modified in 2010 (15). These so-called “Task Force Criteria” (TFC) include major and minor criteria encompassing structural, histologic, electrocardiographic (i.e., depolarization and repolarization), arrhythmic, and family history findings (Table 1). Quantitative TFC criteria were derived from a comparison of 108 ARVC probands to healthy controls, in which cut-offs for major criteria were chosen to achieve 95% specificity. Cut-offs with high specificity invariably result in lower sensitivity, which ranged from 17–58% in a recent validation study (16). In contrast, minor criteria have higher sensitivity (up to 82%) but consequently lower specificity (as low as 67%) (16). Overall, 2 major, 1 major and 2 minor, or 4 minor criteria are required for diagnosis.

For those involved in the care of pediatric ARVC patients, it is important to recognize that the 2010 TFC were derived using a predominantly adult population (mean 38 ± 13 years of age); in fact, only 9 of 108 (8%) probands in the original TFC document were diagnosed between 12 and 18 years of age (15). As such, extrapolation of the TFC for use in pediatric cases should be considered experimental (17). The most important concern for TFC implementation during childhood probably rises for
### TABLE 1 | Diagnostic Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy.

#### I. Structural/functional assessment

| Criteria | Major |
|----------|-------|
| **2D Echocardiography:** | 
| • Regional RV akinesia, dyskinesia, or aneurysm | 
| • and 1 of the following at end diastole: | 
| ◦ PLAX RVOT ≥ 32 mm or PLAX/BSA ≥ 19 mm/m² | 
| ◦ PSAX RVOT ≥ 36 mm or PSAX/BSA ≥ 21 mm/m² | 
| ◦ Fractional area change ≤ 33% | 
| **CMR:** | 
| • Regional RV akinesia or dyskinesia or dyssynchronous contraction | 
| • and 1 of the following: | 
| ◦ RV EDV/BSA ≥ 110 mL/m² (male) or ≥ 100 mL/m² (female) | 
| ◦ RVEF ≤ 40% | 
| **RV angiography:** | 
| Regional RV akinesia, dyskinesia, or aneurysm | 
| **Minor** |
| **2D Echocardiography:** | 
| • Regional RV akinesia, dyskinesia, or aneurysm | 
| • and 1 of the following at end diastole: | 
| ◦ PLAX RVOT ≥ 29 mm or PLAX/BSA ≥ 16 mm/m² | 
| ◦ PSAX RVOT ≥ 32 mm or PSAX/BSA ≥ 18 mm/m² | 
| ◦ Fractional area change ≤ 40% | 
| **CMR:** | 
| • Regional RV akinesia or dyskinesia or dyssynchronous contraction | 
| • and 1 of the following (end diastole): | 
| ◦ RV EDV/BSA ≥ 100 mL/m² (male) or ≥ 90 mL/m² (female) | 
| ◦ RVEF ≤ 45% |

#### II. Tissue characterization

| Criteria | Major |
|----------|-------|
| Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomycocardial biopsy. | 
| **Minor** |
| Residual myocytes 60–75% by morphometric analysis (or 50–65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomycocardial biopsy. |

#### III. Repolarization abnormalities

| Criteria | Major |
|----------|-------|
| Inverted T-waves in leads V1, V2, and V3 or beyond, in individuals >14 years of age (in absence of complete RBBB QRS ≥120 ms). | 
| **Minor** |
| Inverted T-waves in leads V1 and V2, in individuals >14 years of age (in absence of complete RBBB) or in V4, V5, or V6. | 
| Inverted T-waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the presence of complete RBBB. |

#### IV. Depolarization abnormalities

| Criteria | Major |
|----------|-------|
| Epsilon wave (reproducible low-amplitude signals between end of QRS complete to onset of the T-wave) in V1–3. | 
| **Minor** |
| Late potentials by SAECG in ≥1 of 3 parameters in absence of a QRS of ≥110 ms on standard ECG: | 
| ◦ Filtered QRS duration ≥114 ms | 
| ◦ Duration of terminal QRS <40 μV ≥38 ms | 
| ◦ Root-mean-square voltage of terminal 40 ms ≤ 20 μV | 
| ◦ Terminal activation duration of QRS ≥55 ms, measured from the nadir of the S-wave to the end of the QRS, including R’, in V1, V2, or V3, in absence of complete RBBB. |

#### V. Arrhythmias

| Criteria | Major |
|----------|-------|
| Non-sustained or sustained VT of LBBB morphology with superior axis. | 
| **Minor** |
| Non-sustained or sustained VT of RVOT configuration, LBBB morphology with inferior axis or with unknown axis. | 
| • >500 PVCs per 24 h on Holter monitoring |

#### VI. Family history

| Criteria | Major |
|----------|-------|
| First-degree relative with ARVC confirmed by TFC | 
| First-degree relative with ARVC confirmed pathologically at autopsy or surgery | 
| Identification of a pathogenic variant categorized as associated or probably associated with ARVC in the patient under evaluation | 
| **Minor** |
| First-degree relative with ARVC history not possible to confirm by TFC | 
| First-degree relative with SCD <35 years of age due to suspected ARVC | 
| Second-degree relative with ARVC confirmed by TFC or pathologically |

ARVC, arrhythmogenic right ventricular cardiomyopathy; BSA, body surface area; CMR, cardiac magnetic resonance; LBBB, left bundle branch block; EDV, end-diastolic volume; PVC, premature ventricular complex; RBBB, right bundle branch block; PLAX, parasternal long axis; PSAX, parasternal short axis; RV, right ventricular; RVEF, right ventricular ejection fraction; RVOT, right ventricular outflow tract; SAECG, signal-averaged electrocardiogram; SCD, sudden cardiac death; TFC, Task Force Criteria; VT, ventricular tachycardia.
ECG criteria: it is widely accepted that right precordial T-wave inversion V1-3 (major criterion for ARVC diagnosis) is a normal finding in children before puberty (18), and therefore the TFC disregards T-wave inversion as diagnostic criteria prior to the age of 14 years. In addition, epsilon waves (also a major criterion for ARVC diagnosis) are often seen in advanced ARVC cases and are likely to be extremely rare in children and adolescents (19). This potentially results in two major criteria with very little (if any) utility in pediatric patients. A typical ECG for an ARVC patient is shown in Figure 2. Another equally important concern is that echocardiographic and cardiac magnetic resonance (CMR) criteria are not validated in children. Indeed, the revised TFC determined imaging cut-offs based on a cohort with a mean age of 60 years. Since that time, several reports showed that RV end-diastolic volume decreases on average 4% per decade in healthy subjects, which is not accounted for by adjusting for body surface area (20). This suggests that the TFC may be too sensitive in pediatric patients. A typical CMR for an ARVC patient is shown in Figure 3.

Regardless of these limitations, several studies have evaluated the performance of the revised TFC in pediatric or adolescent cohorts. In 2015, Etoom et al. showed that conventional CMR criteria were the strongest contributor to TFC fulfillment in children with ARVC, with almost half of the study population relying on CMR criteria for diagnosis (21). While fatty infiltration and delayed enhancement were rare in this Canadian cohort, a subsequent case series by Slesnick et al. showed that CMR can be highly valuable in determining fibrofatty replacement in pediatric ARVC subjects (22). Similar findings were observed by Steinmetz et al. who showed that any TFC fulfillment on imaging was associated with definite ARVC diagnosis in children with an odds ratio of 8.68 (23). While these studies suggest an important role for imaging in pediatric ARVC evaluation,
the relatively low prevalence of imaging criteria (particularly using echocardiography) and possibly false-positive results in an important subset of patients are cause for concern (24). Several authors have therefore called for the determination of pediatric-specific diagnostic criteria (25, 26). Until the present time, however, the 2010 TFC remain the clinical gold standard for ARVC evaluation in childhood and adolescence. This seems an appropriate decision, as the pathognomonic criteria for ARVC diagnosis in adults are also valid for young people (27), and the clinical characteristics and outcomes are similar between pediatric and adult patients with a definite ARVC diagnosis as per TFC (11).

### GENETICS

**Genetic Architecture of ARVC**

As described above, ARVC is conventionally considered a disease of the cardiac desmosome with autosomal dominant inheritance and age-related reduced penetrance. Pathogenicity of genetic variants in ARVC evaluation is typically attributed based on the American Society of Clinical Genetics (ACMG) criteria; where class 4 (likely pathogenic) and class 5 (pathogenic) variants are considered to be associated with disease (28). In contemporary cohorts, up to two-thirds of patients with definite ARVC per the 2010 TFC have a pathogenic or likely pathogenic (P/LP) variant in one of 5 genes encoding cardiac desmosome proteins (PKP2, DSP, DSG2, DSP, and JUP) (14, 29). Well-characterized variants in TMEM43 and PLN also contribute to ARVC, particularly in specific geographic populations (30, 31). Heterozygous truncating and splice P/LP variants in PKP2 are the most common genetic cause of ARVC (29). DSP, DSG2, and PLN variants are seen more frequently in those with biventricular or left-dominant disease (30, 32–34).

Numerous additional ARVC genes have also been proposed, with uneven quantity and quality of evidence underpinning the ARVC-gene association. Recently, a panel of international experts conducted a rigorous reappraisal of 26 ARVC genes reported in the literature using the semi-quantitative ClinGen framework and found only eight genes had definitive (PKP2, DSP, DSG2, DSP, and JUP) or moderate (PLN, DES) evidence for causing ARVC (Figure 4) (35). Notably, RYR2 was disqualified as an ARVC gene with the investigators reporting that patients and model systems in the literature had catecholaminergic polymorphic ventricular tachycardia (CPVT), not ARVC. Some genes with only limited evidence are relatively newly characterized and more evidence of ARVC causality may accrue over time. Nonetheless, based on current evidence available, the authors suggested that P/LP variants in only PKP2,
DSP, DSG2, DSC2, JUP, TMEM43, PLN, and DES should be used to assign a major genetics criterion when applying the 2010 TFC. Ensuring only genes with substantial evidence of ARVC causality are used to assign the major genetics criterion in the TFC is particularly important for pediatric patients being evaluated for ARVC; they may rely more on this criterion for diagnosis as the TFC disregard right precordial T-wave inversion as a diagnostic criterion before age 14 (18).

Young ARVC patients are particularly likely to harbor one or more P/LP variants. In a cohort of American and Dutch pediatric patients (defined as diagnosis before age 18 or symptomatic presentation of a proband before age 18), 80% had a P/LP variant, significantly more than the 60% of 427 patients presenting as adults (11). Similarly, in a combined cohort of pediatric patients with classic ARVC, biventricular disease, and left-dominant arrhythmogenic cardiomyopathy, 75% of patients with ARVC had at least one P/LP desmosomal variant (36). In the aggregate, genotype positive patients (e.g., harboring one or more P/LP variants) present symptomatically 4 years earlier than gene-elusive probands (14).

Genotype-Phenotype Associations

Broadly, gene-elusive ARVC patients have a similar clinical course to patients with a single P/LP desmosomal variant: a similar proportion develop symptoms, have similar survival free from sustained ventricular arrhythmias, or require transplant (14). Nonetheless, useful data linking genotype to clinical outcomes is emerging. Of particular importance in pediatrics, patients with more than one P/LP variant (including homozygous, compound heterozygous, or di- and tri-genic variants) have younger onset, worse clinical outcomes, and may have an atypical phenotype (37). In a combined US and Dutch cohort of 577 patients with P/LP variants in the desmosomal genes, TMEM43, or PLN, the 4% of patients with more than one variant had significantly earlier occurrence of sustained VT (mean age 28 ± 12 years), worse survival free from a first sustained ventricular arrhythmia, and more frequent LV dysfunction (29%), heart failure (19%) and cardiac transplantation (9%) when compared with those with only one P/LP variant (32). In a cohort of 32 ARVC patients with pediatric onset described by DeWitt et al., multiple potentially pathogenic variants (P/LP and variants of uncertain significance [VUS]) were identified in 9 (28%) patients including 6/9 (67%) with biventricular disease (36). Notably, the presence of multiple P/LP PKP2 variants with at least one on each allele (homozygous or compound heterozygous) seems to herald poor outcomes including pediatric sudden cardiac death and transplant at a young age (36, 38, 39). The presence of loss of function PKP2 variants on each allele (homozygous or compound heterozygous null alleles) may be particularly devastating. There are multiple reports of infants/fetuses with congenital heart disease and poor neonatal outcomes with this genotype (40, 41), consistent with the requirement of plakophilin-2 for cardiac development (42).

Investigators have considered whether genotype is a useful predictor of arrhythmic risk in ARVC, but with only limited success. As noted above, patients with more than one P/LP variant have worse arrhythmic outcomes. Various papers have suggested that particular genes are associated with higher arrhythmic risk, but most of these assertions have not been replicated. Furthermore, in two statistical models developed recently for individualized risk prediction for incident sustained ventricular arrhythmias and rapid sustained ventricular arrhythmias for ARVC patients, genotype was not a significant predictor and is therefore not included in either model (www.arvcrisk.com) (43, 44). This is notable especially because the multicenter international cohorts included to derive the models were the largest cohort of ARVC patients ever assembled. One exception to the limited utility of genotype in predicting arrhythmic risk is the TMEM43 c.1073C>T; p.Ser358Leu variant which was initially identified in a large number of patients and families from Newfoundland. This variant is associated with a highly penetrant and arrhythmogenic subtype of ARVC (45, 46). Risk of sudden cardiac death from ventricular arrhythmias is particularly high in males. As such, the literature suggests that genotype predicts arrhythmic risk in ARVC less well than demographic and clinical predictors.

In contrast, there is substantial evidence that the extent of LV involvement and heart failure is associated with genotype. A large study in 577 ARVC probands and family members with P/LP variants from North America and The Netherlands showed that prevalence of left ventricular dysfunction and heart failure varied substantially by genotype (32). LV dysfunction (defined as LV ejection fraction <55%) was seen in 78 (14%) patients while 28 (5%) experienced clinically-recognized congestive heart failure during follow-up. As shown in Figure 5, PKP2 carriers were least likely to have LV dysfunction (9%), whereas those with a P/LP DSP variant had significantly more frequent LV dysfunction (40%) and heart failure (13%). PLN variant carriers presented at a significantly older age yet had worse long-term prognosis, with more LV dysfunction and heart failure. The observation that P/LP variants in DSP and PLN disproportionately affect the LV has been replicated in numerous studies including in pediatric patients with DSP variants (36). Furthermore, as discussed earlier, multiple P/LP variants heralded worse outcomes, tripling the prevalence of heart failure (32). The latter was also found in a British study, in which four of eight patients who underwent transplantation or died due to heart failure had multiple genetic variants (47). It is also important to realize that the influence of founder variants is significant: for example, the homozygous p.F531C variant in DSG2 was associated with a fully penetrant heart failure phenotype in a Chinese cohort (34), while the TMEM43 p.S358L variant in addition to conveying a high risk of sudden cardiac death is associated with LV dysfunction (31).

Finally, there is increasing evidence that ARVC presenting with chest pain and myocardial enzyme release in the setting of normal coronary arteries ('hot phase') is particularly common in patients with DSP P/LP variants (48–50). These myocarditis-like episodes of acute myocardial injury are particularly common in pediatric ARVC, may recur, and can be familial. Therefore, recurrent myocarditis in a child, or pediatric myocarditis in the setting of a concerning family history should prompt consideration for genetic testing and for evaluation for ARVC.
**Genetic Testing**

Genetic testing is recommended for patients with ARVC to confirm the diagnosis, inform management, and inform cascade testing of the family (2, 51). More information on cascade genetic testing can be found below. A multidisciplinary team approach including cardiology, pathology, genetics, and genetic counseling is recommended and valued by patients (2). Best practices for genetic testing for ARVC have been reviewed elsewhere (2, 52), but several aspects that are particularly relevant to the pediatric population are described below and summarized in Table 2.

**LESSONS LEARNED FROM NAXOS DISEASE**

It was as early as 1986 when the first observation of an ARVC phenotype associated with palmoplantar keratoderma (PPK) and wooly hair (WH) was published. The syndrome was named “Naxos disease” after the Aegean island where it was initially observed, and it was reported under this name in the World Congress on Cardiomyopathies in Warsaw in 1993.

Over the years that followed, Naxos disease was mapped to chromosome 17q21 and the causative pathogenic variant was identified: a 2 base-pair deletion in the desmosomal JUP gene (Pk2157del2TG), truncating the C-terminal of the protein (53). A decade after the first publication, a similar phenotype was reported by Rao et al. and by Carvajal et al. in patients from India (1996) and Ecuador (1998), respectively (54). The cutaneous phenotype consisting of PPK and WH seemed identical to that of Naxos syndrome, while the cardiomyopathy presented with predominant LV involvement diagnosed as dilated cardiomyopathy. Molecular genetic investigations in the families from Ecuador revealed a recessive variant in DSP (55). In a later report on an Ecuadorian patient, the name of Carvajal syndrome was used for the first time (56). It is worth mentioning, however, that Hamill et al. had reported on a syndromic phenotype of dilated cardiomyopathy with arrhythmias and ectodermal dysplasia in three unrelated young toddlers as early as 1988 (57). The children presented with episodes of recurrent VT by the age of 18 months, while chest pain and congestive heart failure developed by the 3rd year of life. Severe biventricular involvement with fibrosis and moderate inflammatory infiltrates was detected. Alopecia preceded the cardiac phenotype, while...
lesions of PPK, nail and dental anomalies were noted despite their young age.

The homozygous pathogenic JUP variant is identified in other Aegean islands as well as in Turkey (58, 59). The prevalence of Naxos disease in Greek islands reaches 1:1,000 (60). Over the years, an increasing number of families with the phenotype of WH, PPK and ARVC/ACM left-dominant arrhythmogenic cardiomyopathy have been reported. Most of these reports concern pathogenic DSP variants (54, 61, 62). It is important to note that patients with Naxos or Carvajal disease are rare (outside of endemic regions), and that they present with a distinct cutaneous and cardiac phenotype. Regardless, many lessons were learned based on Naxos disease patients, as described below.

The Cutaneous Phenotype

In patients with Naxos disease, WH is apparent from birth. Interestingly, observant members of affected families have mentioned it as a harbinger of a severe heart disease (personal communication). In the largest reported series of pathogenic DSP variant carriers, WH was shown to have high specificity in detecting subjects who will develop a cardiomyopathy (62). In some patients with JUP/homozygous pathogenic variants (or biallelic), sparse WH or even alopecia were reported. Alopecia has been related mostly to DSP variants (63).

Keratotic lesions on the palms and soles generally develop during the second year of life when the child is using hands and feet (60, 63). In early infancy, eczematous lesions, fragile skin or even erosion and ulcers have been observed on the perioral and sacral areas or dorsal surfaces of the hands and legs (Figure 6). Nail dystrophy and dental anomalies may be part of the phenotype particularly of pathogenic DSP variants (61, 64). Pemphigus-like vesicular lesions on palms, soles and knees have been reported as well (65). Of note, neonatal lethal epidermolysis has been reported in both JUP and DSP homozygous variants (63, 66, 67).

Immunohistology of non-lesional skin on the forearm in pathogenic DSP variant carriers revealed that desmoplakin is irregularly localized in the basal layers of epidermis instead of the membranous distribution observed in normal skin. The same, albeit to a lesser extent, is observed for plakoglobin. In areas of clinically “normal” skin, reduced expression of connexin43 is also observed (62). Expression of desmosomal proteins in basal layers of epidermis are more representative of those expressed in myocardium.

The Cardiac Phenotype

While skin defects become apparent early in life, diagnostic features of ARVC do not develop until late puberty (54). The earliest observed cardiac abnormality was in a 5-year-old girl with the cutaneous phenotype of Naxos disease, homozygous for the JUP pathogenic variant. She presented with 14,000/24 h ventricular ectopics, without any detectable myocardial imaging change while, after a non-cardiac death, gross pathology of the whole heart and regular histology were normal. However, electron microscopy of the myocardium revealed biventricular gap junction remodeling and abnormal immunohistology for both connexin43 and plakoglobin at cell-cell junctions (68). Clinical presentation of ARVC as an episode of acute myocarditis has been highlighted also in a boy with Naxos disease. He had been followed-up since infancy due to

---

**TABLE 2 | Pediatric genetic testing overview.**

| Who to test?          | When to test?                  | How to test?                                                                 | Why to test?                                      |
|----------------------|--------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------|
| **First test in family** | - Youngest onset               | - Full coverage of ARVC genes                                               | - To inform cascade screening of family.          |
|                      | - Worst phenotype              | - Test that includes detection of copy number variants                      | - Genotype-guided care                            |
|                      | - After complete cardiovascular evaluation | - Large panel a reasonable choice                                            |                                                  |
|                      | - After constructing pedigree  | - With psychosocial support and multidisciplinary team                      |                                                  |
|                      |                                | - Targeted sequencing of family variant(s)                                  |                                                  |
|                      |                                | - With psychosocial support and genetic counseling                         |                                                  |
| **Cascade testing**  | - First degree relatives ≥ age 10, younger testing reasonable<sup>a,b</sup> | - In conjunction with baseline cardiovascular screening                      | - Determine need for longitudinal cardiovascular screening |
|                      | - Families with a P/LP variant | - Pathogenic or likely pathogenic variant as assessed by criteria published by the American College of Medical Genetics and Genomics and Association for Molecular Pathology (28). |

**References to substantiate statement:** <sup>a</sup> = (57); <sup>b</sup> = (2).

P/LP, pathogenic or likely pathogenic variant as assessed by criteria published by the American College of Medical Genetics and Genomics and Association for Molecular Pathology (28).
the phenotype of WH and PPK, and he was a homozygous carrier of the pathogenic JUP variant (69). Newly developed patchy LGE changes on CMR and progression of repolarization changes were documented at the age of 14 years following an episode of chest pain (Figure 7). Therefore, a thorough cardiac investigation should be considered in any child with the phenotype of Naxos disease upon an episode of chest pain to detect potentially emerging myocardial defects or ARVC progression.

Symptoms of right heart failure in Naxos disease commonly appear later in the disease course. Isolated reports in toddlers homozygous or compound heterozygotes for DSP variants show that cardiomyopathy is clinically manifest with severe biventricular or predominant LV involvement leading to heart failure (60, 63, 70).

Cardiac biopsies performed in patients homozygous for a pathogenic JUP variant revealed fibrofatty replacement of RV myocardium. Inflammatory infiltrates were observed particularly when the biopsy was performed at the time of clinical progression (60). In a patient who fulfilled TFC for ARVC diagnosis and died suddenly at the age of 20 years, the RV showed extensive myocardial loss with fibrofatty replacement at subepicardial and medio-mural layers being regionally transmural with aneurysmal formations (68). While the LV appeared unaffected on gross pathology, areas of myocardial loss with fibrofatty substitution or replacement fibrosis with lymphocyte infiltrates were revealed.

**FIGURE 7** | Example of a boy with Naxos disease, homozygous for a pathogenic JUP variant, on regular follow-up since the age of 1 year old. He was asymptomatic until the age of 14 years when he was admitted with chest pain, increased troponin-I levels up to 20 µg/L (normal values: 0.04 µg/L), complex ventricular extrasystoles and changes on 12-lead ECG. (A) ECG recordings in 25 mm/s, 10 mm/mV, at the first (1D), second (2D), third (3D) and eighth (8D) days of hospitalization. Newly developed repolarization changes are observed. (B) Phase-sensitive inversion recovery CMR images to detect LGE 1 year prior to hospitalization (left) and the second day of hospitalization (right) are shown. No functional changes were observed on either CMR in both ventricles (i.e., normal LV and RV function). However, LGE was detected (arrow) in the LV myocardium (right) as compared to the isolated involvement of RV free wall, a year previously (left), suggesting progression of disease. CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular. Source: (69), obtained with permission.
FIGURE 8 | Surgical sample from the anterior wall of the right ventricle of a 19-year-old patient with Naxos disease. Surviving myocardial fibers with some vacuolization, surrounded by fibrosis (haematoxyline-eosine-stained, magnification x 100) (A). Postmortem samples from the left ventricle of a patient with Naxos disease, who died suddenly at the age of 20 years. Myocardial loss with replacement fibrosis and lymphocyte infiltrates (haematoxylin-eosin-stained sections) (B). On confocal microscopy images (same patient) of the left ventricle, there is diminished signal of plakoglobin and connexin 43 at intercellular junctions (C).
patients. In another study, features consistent with myocardial inflammation and severe ventricular arrhythmias were evident in six out of 32 pediatric patients (36). On a molecular level, ARVC is linked to local myocardial production of cytokines and alterations in the balance of circulating inflammatory cytokines.

**NATURAL HISTORY**

Three stages in ARVC evolution have been suggested: A “concealed” stage in which the disease is not evident on cardiac screening when only molecular changes can be detected; an “electrical” stage with abnormalities on ECG or Holter monitoring, but a normal or near-normal structure on conventional imaging; and a “structural” stage with expression of the full phenotype. Genotype-phenotype differences and the risk of life-threatening arrhythmias in the concealed stage remain controversial.

The symptomatic disease presentation in children has been reported around the 15th year of life, mostly in series with autosomal dominant ARVC (78). Frequent premature ventricular complexes (PVCs) and episodes of non-sustained VT have been observed as the first electrical manifestations in pediatric ARVC, whilst episodes of syncpe or even cardiac arrest have been recorded in young individuals (11). In patients diagnosed under the age of 21 years, cardiac arrest was observed in probands only at a mean age of 15.3 years, and episodes of sustained VT at 16.7 years (11). Electrocardiographic and Holter abnormalities usually precede imaging changes of ventricular myocardium in children (85). Structural abnormalities in children with ARVC are often mild, and involve focal subtricuspid dyskinesia with preserved global function rather than severe RV enlargement (17). When biventricular involvement exists, ARVC is diagnosed in significantly younger age (12.4 ± 5.0 years) as compared to classic ARVC (16.7 ± 2.0 years) (36). Indeed, LV involvement has been related to worse prognosis in children with ARVC (58, 86).

**CASCADE SCREENING**

Given the strong familial disease pattern of ARVC, predictive genetic testing and/or cardiac evaluation should be performed in family members of ARVC probands to detect early signs of disease and prevent sudden cardiac death. Indeed, previous studies have shown that approximately one in three family members will develop ARVC (87–89) The yield of screening however varies due to the age-related and incomplete penetrance, and the ARVC disease spectrum can be diverse even among those carrying the same pathogenic variant (85). Ideally, cascade (genetic and/or cardiologic) screening is therefore performed within the confines of a multidisciplinary cardiovascular genetics program that is familiar with the complexity of this disease (2). The following sections will describe the evidence surrounding the questions of genetic as well as cardiac screening for ARVC.

**Cascade Genetic Testing**

First, a pedigree should be constructed before genetic testing in the family is started. If a family has multiple affected members, the individual with the youngest presentation and/or most severe disease should be tested first. This is recommended to maximize the chance that if there are multiple P/LP variants in the family they are all identified. As described earlier, a pediatric patient is particularly likely to have more than one P/LP variant.

Second, while a limited ARVC-specific panel is a reasonable choice for first-line genetic testing, increasingly large cardiomyopathy and arrhythmia next generation sequencing panels are used. A recent study has shown using these larger panels (i.e., next generation sequencing of cardiomyopathy and primary arrhythmia-associated genes) do increase detection of clinically informative P/LP variants although at the cost of increased detection of VUSs (90). Nonetheless, as children with ARVC may be particularly likely to have multiple variants, potentially in both desmosomal and non-desmosomal genes, using a larger panel is reasonable to maximize detection of the full genotype.

Third, a recent study by Van Lint et al. of 501 American, Dutch, and German ARVC probands found that P/LP ARVC-associated variants are almost never de novo (29). Therefore, if P/LP variant(s) are identified in a child, it is very likely a parent has transmitted the variant and so the parent and also any siblings are at risk. Anticipatory guidance for the family that this is a likely outcome is important.

Finally, children may also be offered genetic testing as part of cascade genetic screening. The age at which pre-symptomatic testing for ARVC is offered varies both within and between nations. Regardless, the decision can be complicated for some families, particularly as detection of a desmosomal variant will likely result in a discussion of the risks and benefits of exercise restriction. A decision-support tool for presymptomatic pediatric ARVC testing for has recently been developed and is publicly available (redcap.link/decision_aid; University of Alberta, accessed 6/20/21).

**Cardiac Screening: “Who” and “When” to Screen for ARVC**

Several research groups have shown that penetrance of ARVC is age-related: ARVC rarely manifests before the age of 10 years, and disease expression increases throughout life with the majority of pathogenic variant carriers expressing disease after 60 years of age (89). Some have suggested that this may be due to the developmental maturation of the intercalated disk, which completes at approximately 10 years after birth and subsequently requires time to get damaged by external and internal factors to ultimately elicit the ARVC phenotype (91). Consequently, most patients are diagnosed with definite ARVC between the second and fourth decade of life. Likewise, a recent study showed that the incidence of newly diagnosed ARVC follows an inverted U-shaped curve, which peaks in the 30–40 year age groups and is lowest at either end of the disease spectrum (Figure 9) (89).

Two recent studies using the same multicenter cohort of 502 definite ARVC patients described clinical features of patients with early (<18 years) or late (>50 years) ARVC presentation (11, 92). Overall, 15% presented as children or adolescents, of whom one in four presented with sudden cardiac death or resuscitated sudden cardiac arrest. Conversely, 21% of ARVC patients
presented after the age of 50 years, often with hemodynamically stable VT. While this suggests that all family members of ARVC patients are at risk of developing possibly lethal consequences of this disease, risk of ARVC among family members is not uniform. In a recent study of 274 first-degree family members of ARVC probands, predictors of ARVC diagnosis included symptoms, being a sibling to the proband, and presence of a pathogenic genetic variant (89). Recognition that symptomatic subjects have increased risk of ARVC is intuitive and should be a red flag in any clinical evaluation. The higher risk of disease in siblings as compared to parents and children may be considered surprising and was not completely explained by correcting for age in this study. This may suggest that other factors such as genetic background or shared environmental influences (e.g., exercise participation) impact disease development among family members. Consistent with a genetic inheritance pattern, pathogenic variant carriers have an increased risk of developing disease. Presence of a pathogenic genetic variant even conferred a 6-fold increased risk of disease in a cohort of 302 relatives from 93 families (87). These studies may help clinicians single out family members who should be more closely followed.

**Cardiac Screening: “How to Screen” for ARVC**

As described previously, ARVC is diagnosed by a combination of clinical tests as defined in the 2010 TFC. It should therefore be inferred that a full baseline evaluation including all TFC-prescribed tests is necessary to diagnose (or rule out) ARVC with certainty. However, many research groups have provided evidence that diagnostic yield differs among tests. ARVC is a progressive disease (93), and therefore screening for disease development should be performed at multiple time points using the most useful combination of tests. Almost uniformly, studies have shown that 12-lead ECG and Holter monitoring are among the most sensitive tests for ARVC evaluation, with abnormal test results approaching 90% in affected patients (16). However, almost all these prior studies were cross-sectional in design, and did not consider progression that may have occurred on these tests. Te Riele et al. recently published a report on longitudinal follow-up in family members of ARVC probands (85). In their study, the authors followed 37 asymptomatic family members over a mean of 4.1 ± 2.3 years of follow-up. Overall, 11 (30%) subjects had evidence of disease progression (defined as the development of a new TFC at last follow-up, that was absent at enrolment) and 5 (14%) family members were diagnosed with definite ARVC at last follow-up. Disease progression was most often observed on 12-lead ECG (14%) or Holter monitor (11%), whereas progression on CMR (3%) was rare. In addition, “electrical” changes on ECG and Holter monitor preceded detectable “structural” changed on CMR, and the presence of both an abnormal “electrical” and “structural” substrate magnified arrhythmic risk (94). Taken together, these studies suggest that screening efforts may be most efficient by focusing on ECG and Holter monitoring, while imaging testing should be reserved for selected cases with symptoms and/or abnormal ECG or Holter monitoring tests. Of note, this does not substitute a full baseline evaluation and regular follow-up as per TFC.

**Recommendations for Screening of Pediatric Family Members**

In case of a pediatric family member, cascade screening is complicated by the legal and psychological issues that accompany medical interventions in a healthy minor. As such, the Heart Rhythm Society (HRS) Expert Consensus Statement recommends to start ARVC screening at an age when disease expression is expected, i.e., at 10–12 years (2). In contrast, the Heart Failure Society of America (HFSA) suggests that screening should start at an age of 6 years and should be intensified between the ages of 13–19 years (51). Both guidelines recommend the use...
of genetic testing as well as cardiac evaluation with an ECG, 24-h Holter monitor, and imaging (echocardiography or CMR). Given the peak of ARVC diagnoses in adolescents and young adults, the onset and interval of screening should be adjusted by age, and possibly several other factors including symptomatology and athletic activity.

**MANAGEMENT OF ARVC**

**Lifestyle/Exercise**

In ARVC patients, frequent high-intensity aerobic exercise has been associated with worse clinical outcomes in patients and increased penetrance in at-risk genotype positive relatives. Data from multiple ARVC cohorts consistently shows that competitive or frequent vigorous intensity endurance exercise is associated with earlier onset, sudden cardiac death presentation, worse survival free from ventricular arrhythmias in follow-up, worse RV and LV structure and function, and increased likelihood of heart failure and transplant (95–99). This pattern holds for both gene elusive patients (100) and those with a P/LP variant (95). Reducing exercise after diagnosis results in lower risk of VT and implantable cardioverter-defibrillator (ICD) therapy in follow-up (95, 101). Therefore, although wording varies, guidelines consistently recommend that patients with a definite ARVC diagnosis refrain from competitive or frequent high-intensity aerobic exercise. The evidence base for exercise guidance for ARVC patients and published clinical recommendations have been recently comprehensively summarized by Zorzi et al. (102).

Exercise has a similar negative impact on patients with the TMEM43 p.S538L variant, with recent publications showing athletic individuals had earlier onset of ventricular arrhythmias and a considerably worse survival free from appropriate ICD-therapy in follow-up (103). In contrast, a recent publication of a cohort of patients and family members with DSP P/LP variants suggested history of exercise was less common in probands and that there was no association of exercise history with sustained ventricular arrhythmias or RV or LV dysfunction (48). While this study requires replication, particularly since it was not designed to measure the patient’s exercise history, it does highlight the potential for genotype-specific exercise guidance in the future. Presently, it is important to recognize that current professional recommendations may not accurately reflect predominantly LV disease often associated with DSP and PLN variants as there is little data to draw on for these populations.

There has been limited information specifically focused on the impact of exercise in pediatric patients. Te Riele et al. analyzed exercise participation in 88 patients with P/LP variants (16 pediatric pediatric-onset, 72 adult-onset) who underwent detailed exercise interviews (11). As shown in Figure 10, pediatric patients were significantly more likely than those with adult-onset to have been involved in endurance (Class C) athletics before the age of 18 years (13 of 16 [81%] vs. 39 of 72 [54%]). Specifically, pediatric-onset ARVC was associated with endurance athletics in the 10- to 12-year (p = 0.047), 12- to 14-year (p = 0.017), and 14- to 16-year (p = 0.026) age categories (Figure 10A). In addition, patients with pediatric-onset disease participated in more annual hours of exercise during adolescence compared with patients with adult-onset ARVC, although this did not reach statistical significance (Figure 10B). Also of note, in a recent study of 101 family members of ARVC patients with P/LP variants (mostly in PKP2), Wang et al. showed that the difference in exercise between individuals who later developed ARVC and those who remained unaffected was higher in females than in males (104). Girls who had done high-dose exercise in adolescence had the worse survival free from diagnosis. This highlights the importance of “counseling adolescent (and adult) family members with a positive genetic test but who are phenotype negative that competitive or frequent high-intensity exercise is associated with increased likelihood of developing ARVC and ventricular arrhythmias” and engaging in shared decision-making regarding appropriate exercise participation.

**FIGURE 10** | Comparison of exercise intensity and duration during adolescence between patients with pediatric and adult-onset ARVC. Pediatric patients engaged in higher intensity exercise (A) and performed more annual hours of exercise (B) during adolescence than arrhythmogenic right ventricular cardiomyopathy patients with Adult onset. Error bars indicate 95% confidence interval. * indicates statistically significant at p < 0.05. ARVD/C, arrhythmogenic right ventricular cardiomyopathy. Source: (11), obtained with permission.
with the family as recommended by recent Heart Rhythm Society professional guidelines developed with multiple international cardiology and genetics societies (2).

Medical Management and Ablation

Medical therapy plays an important role in the management of patients with ARVC. It must be recognized that there are no prospective randomized or non-randomized clinical trials of any form of medical therapy in ARVC patients of any age. In this section, we will outline the approach to medical therapy employed by the Johns Hopkins ARVC program. It is our impression that this approach is similar to that employed at other high volume ARVC centers.

The cornerstone of medical therapy in ARVC is the use of beta blockers. We believe that the rationale for use of beta blockers is compelling. First, it is well established that beta blockers are the only form of medical therapy that has been shown to reduce the risk of a cardiac arrest in patients with various types of heart disease. Second, beta blockers have been proven to be of benefit in the treatment of patients with various forms of heart failure. Third, a great proportion of cardiac arrests that occur in ARVC patients occur during exercise (95), a situation where catecholamine levels are high. And fourth, Denis and colleagues have demonstrated that a high dose isoproterenol infusion (45 mcg/min) triggers long runs of polymorphic VT in ARVC patients and that this dramatic form of VT responds rapidly to administration of an intravenous beta blocker (105). As such, while conclusive evidence based on (non-)randomized trials is lacking, it is likely that beta-blockers (at least to some degree) prevent ventricular arrhythmias.

Angiotensin converting enzyme (ACE) inhibitors also play an important role in the management of ARVC patients with significant structural disease and RV and/or LV dysfunction. While there are no studies proving their value in ARVC patients, there are many trials demonstrating the critical role of ACE inhibitor therapy in patients with ischemic and non-ischemic forms of dilated cardiomyopathy. We have a low threshold to institute ACE therapy once a beta blocker has been started, assuming the patient tolerates it. Because this is an empiric approach and not proven, we stop the ACE inhibitor if the patient has side effects.

A third form of therapy that we do not employ but you should be aware of is the use of diuretics and nitrates to unload the RV. Fabritz and colleagues demonstrated the value of this approach in a mouse ARVC model (106). More recently, Kalantarian and colleagues published a retrospective analysis of six ARVC patients placed on load-reducing therapy with nitrates and diuretics. The authors reported less RV enlargement during a mean follow-up of 3 years (107). Despite these two studies showing a potential benefit, we have not employed this form of therapy due to the likelihood of side effects and limitations in the design of these small trials. This is clearly an area for further investigation.

A final type of medical therapy commonly used in ARVC patients are antiarrhythmic drugs. Wichter and colleagues demonstrated the value of sotalol in ARVC patients decades ago (108). In contrast, a more recent study by Marcus showed little value of sotalol, and concluded that amiodarone had greater efficacy (109). Of note, there has been increased interest in the use of flecainide. Ermakov published a small series of combination antiarrhythmic therapy including flecainide (110). Moreover, Cerrone has shown in an animal model that flecainide is of value in a PKP2 mouse model of ARVC (75). Based on these trials, a prospective randomized clinical trial of flecainide is under way, which is a short-term cross-over study where the endpoint is suppression of PVCs. At present, our preferred antiarrhythmic drug in ARVC patients is flecainide, and if not tolerated or effective we employ sotalol. While we have used amiodarone in the past, we much prefer proceeding to VT ablation rather than start a young person on amiodarone.

Indeed, radiofrequency ablation has gained popularity for ARVC management over the years. While initial studies have indicated that endocardial ablation procedures have a high VT recurrence rate in ARVC patients (111), much better results are obtained with a primary epicardial, or combined endo-epicardial approach (112, 113): in these studies, VT-free survival at 3 years follow-up may even be as high as 85% (114). It should be noted that these ablation results were obtained in high-volume tertiary care centers, and that these results may not pertain to centers that are unfamiliar with ARVC management and its predominantly epicardial substrate (115).

Arrhythmic Risk Stratification/ICD Implantation

Patients with ARVC have an average annual risk of approximately 10% to develop potentially life-threatening ventricular arrhythmias or sudden cardiac death (116). Of primary concern is sudden cardiac death prevention, for which the only effective treatment is the placement of an ICD. However, this treatment is invasive with inherent complication risk, and can impose physical or psychological burden to the patient. As such, estimating the probability of developing ventricular arrhythmias is pivotal to protect those at high risk, while at the same time limiting interventions among those who are unlikely to derive benefit from their results.

Over the years, many studies have evaluated risk factors for ventricular arrhythmias in ARVC. A full overview of risk factors goes beyond the scope of the present manuscript and can be found elsewhere (116). In short, established predictors of ventricular arrhythmia in ARVC include male sex, younger age at diagnosis, RV systolic dysfunction, prior non-sustained VT, syncope, and high PVC count on Holter monitoring.

Several expert consensus documents recently consolidated the available evidence on arrhythmic risk stratification in ARVC, including the 2015 international task force consensus statement on management of ARVC (117), the 2017 AHA/ACC/HRS guideline for management of ventricular arrhythmias (118), and the 2019 HRS consensus statement on evaluation, risk stratification and management of arrhythmogenic cardiomyopathy (2). While these publications presented a large step forward for clinicians taking care of ARVC patients, several limitations remained: first, these algorithms were based on expert opinion; second, all guidelines were flowchart-based and did not consider the potential interactive effects.
te Riele et al. Pediatric Arrhythmogenic Right Ventricular Cardiomyopathy

Figure 11 | Multivariable risk model to predict occurrence of first sustained ventricular arrhythmia in ARVC patients without prior arrhythmic events. Left panel denotes arrhythmia-free survival in 528 definite ARVC patients in North-America and Europe. Middle panel shows the derivation of a multivariable model for ventricular arrhythmia occurrence, using seven easily available clinical predictors. Right panel shows observed event-free survival stratified by predicted risk in the model. Source: (43), obtained with permission.

of combinations of risk factors; and third, translation to absolute risks was lacking. To address these shortcomings, a large transatlantic network of 15 centers in North-America and Europe recently published a multivariable model that enables quantitative individualized prediction of arrhythmic risk in ARVC (Figure 11), which is available for use at www.arvcrisk.com (43, 44). As of today, several studies validated the performance of the risk model in external cohorts, with good to excellent results (119–121). For the purpose of this review, it is however important to highlight that only a minority of study subjects were in the pediatric age range, and future studies should confirm the utility of the risk model in children and adolescents.

CONCLUSION

ARVC is an inherited heart disease characterized by fibrofatty infiltration predisposing the patient to ventricular arrhythmias and slowly progressive RV and LV dysfunction. The seminal description of Naxos disease led to the identification of genetic variants in the cardiac desmosome that are associated with ARVC. The disease is typically inherited in an autosomal dominant fashion, with incomplete penetrance and variable expressivity suggesting a strong role for environmental factors. Indeed, exercise exposure and myocardial inflammation have been linked to cardiac disease expression. Given that arrhythmias may occur early in the disease course, early screening and disease detection is of great importance. While there is no definitive cure for ARVC, treatment with beta blockers/antiarrhythmic medication, ACE inhibitors and load reducing therapy may reduce symptoms. Over recent years, several societies provided guidelines for ICD implantation. Future efforts should combine (inter-)national registries to improve our understanding of the clinical characteristics, genetic background, and prognostic factors associated with adverse outcome in ARVC patients at the pediatric age range.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

AR, CJ, HC, and AT conceived and designed the research and drafted the manuscript. AR and AT made critical revision of the manuscript for key intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

The Johns Hopkins ARVD/C Program is supported by the Leonie-Wild Foundation, the Leyla Erkan Family Fund for ARVD Research, the Dr. Francis P. Chiramonte Private Foundation, the Dr. Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family, the Peter French Memorial Foundation, and the Wilmerding Endowments. AR is supported by CVON e-DETECT, the Dutch Heart Foundation (2015T058) and CVON PREDICT Young Talent Program.
REFERENCES

1. Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, et al. Definition and treatment of arrhythmic cardiomyopathy: an updated expert panel report. Eur J Heart Fail. (2019) 21:955–64. doi: 10.1002/ejhf.1334

2. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmic cardiomyopathy: Executive summary. Heart Rhythm. (2019) 16:373–407. doi: 10.1016/j.hrthm.2019.09.019

3. Marcus FI, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmic cardiomyopathy: Executive summary. Heart Rhythm. (2019) 16:373–407. doi: 10.1016/j.hrthm.2019.09.019

4. Sen-Chowdhrey S, Syrrix P, Ward D, Asimaki A, Sevalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. (2007) 115:1710–20. doi: 10.1161/CIRCULATIONAHA.106.660241

5. Chungsomprasong P, Hamilton R, Luining W, Fatah M, Yoo SJ, Grosse-Wortmann L. Left ventricular function in children and adolescents with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. (2017) 119:778–84. doi: 10.1016/j.amjcard.2016.11.020

6. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. (1988) 318:129–33. doi: 10.1056/NEJM198801213180301

7. Beffagna G, Zorzi A, Pilichou K, Perazzolo Marra M, Rigato I, Corrado D, et al. Familial occurrence of right ventricular dysplasia/cardiomyopathy. Eur J Heart Fail. (2020) 22:537–46. doi: 10.1002/ejhf.1534

8. Nava A, Thiene G, Canciani B, Scognamiglio R, Daliento L, Rigato I, Corrado D, et al. Familial occurrence of right ventricular dysplasia/cardiomyopathy. Eur J Heart Fail. (2020) 22:537–46. doi: 10.1002/ejhf.1534

9. Protonotarios N, Tsatsopoulou A, Patsourakos P, Alexopoulos D, Gezerlis P, et al. Right ventricular cardiomyopathy/dysplasia. Eur J Heart Fail. (2020) 22:537–46. doi: 10.1002/ejhf.1534

10. Groeneweg JA, Bhonsale A, James CA, McKenna AS, Dooijes D, Tichnell C, et al. Arrhythmogenic right ventricular cardiomyopathy (ARVC) in children and adolescents: importance of CMR within the Task Force Criteria for the diagnosis of ARVC in children and adolescents. J Am Coll Cardiol. (2015) 65:987–95. doi: 10.1016/j.jacc.2014.12.041

11. Slesnick T, Parks WJ, Fouklis J, Al-Haddad E, Vickery J, Eskarous H, et al. Cardiac magnetic resonance imaging macroscopic fibro-fatty infiltration of the myocardium in pediatric patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Fetal Pediatr Pathol. (2020) 39:455–66. doi: 10.1080/15513815.2019.1675108

12. Steinmetz M, Krause U, Lauerer P, Konietzke F, Agugliaro R, Ritter CO, et al. Diagnosis of ARVC in pediatric patients applying the revised task force criteria: importance of imaging, 12-lead ECG, and genetics. Pediatr Cardiol. (2018) 39:1156–64. doi: 10.1007/s00246-018-1875-y

13. Deshpande SR, Herman HK, Quigley PC, Shinnick JK, Cundiff CA, Calharp S, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (arc/d): review of 16 pediatric cases and a proposal of modified pediatric criteria. Pediatr Cardiol. (2016) 37:646–55. doi: 10.1007/s00246-015-1327-x

14. Sreetharan S, MacIntyre CJ, Fatah M, Warren AE, Wilson GJ, Hamilton RM. Clinical utility of endomyocardial biopsies in the diagnosis of arrhythmogenic right ventricular cardiomyopathy in children. Pediatr Res. (2018) 84:552–7. doi: 10.1038/s41390-018-0093-5

15. Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation and Genomics and the Association for Molecular Pathology. Circ Genom Precis Med. (2015) 17:405–24. doi: 10.1177/1942813015588237

16. Platonov PG, Calkins H, Hauer RN, Corrado D, Svendsen JH, Platonova M, et al. Applications of epsilon waves: Implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. (1982) 65:384–98. doi: 10.1161/01.CIR.65.2.384

17. McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DJ, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: evidence supporting the concept of arrhythmogenic right ventricular cardiomyopathy. Eur J Heart Fail. (2012) 14:1199–207. doi: 10.1038/ejhf.2011.119

18. Malgrange F, Zorzi A, Michieli P, Perazzolo Marra M, Basso C, et al. Misdiagnosis of arrhythmogenic right ventricular cardiomyopathy in children. Circ Genom Precis Med. (2019)

19. Hodgkinson KA, Connors SP, Meiner N, Haywood A, Young TL, McKenna WJ, et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43. Clin Genet. (2013) 83:321–31. doi: 10.1111/j.1399-0004.2012.01919.x
32. Bhonsale A, Groeneweg JA, James CA, Doijies D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. *Eur Heart J.* (2015) 36:847–55. doi: 10.1093/eurheartj/ehu509
33. Castelletti S, Vischer AS, Syrris P, Crotti L, Spazzolin C, Ghidoni A, et al. Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. *Int J Cardiol.* (2017) 249:268–73. doi: 10.1016/j.ijcard.2017.05.018
34. Chen L, Rao M, Chen X, Chen K, Ren J, Zhang N, et al. A founder homozygous DSG2 variant in East Asia results in ARVC with full penetrance and heart failure phenotype. *Int J Cardiol.* (2019) 274:263–70. doi: 10.1016/j.ijcard.2018.06.105
35. James CA, Jongbloed JDI, Hershberger RE, Morales A, Judge DP, Syrris P, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. *Circ Genom Precis Med.* (2021) 14:e003273. doi: 10.1161/CIRCGEN.120.003273
36. DeWitt ES, Chandler SF, Hylind RJ, Beausejour Ladouceur V, Blume JD, et al. Genetic evaluation of cardiomyopathy-a heart failure society of America Practice Guideline. *J Card Fail.* (2018) 24:281–302. doi: 10.1016/j.cardfail.2018.03.004
37. James CA, Syrris P, van Tintelen JP, Calkins H. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. *Eur Heart J.* (2020) 41:1393–400. doi: 10.1093/eurheartj/ehaa141
38. Klauke B, Gaertner-Rommel A, Schulz U, Kassner A, Zimmer T, et al. Recessive mutation in desmoplakin disrupts heart development in zebrafish. *Circ Genom Precis Med.* (2011) 4:1850–8. doi: 10.1093/eurheartj/ehz103
39. Chen K, Rao M, Guo G, Duru F, Chen X, et al. A founder homozygous Plakophilin 2-gene mutation. *Am J Cardiol.* (2017) 11:e002397. doi: 10.1161/CIRCGEN.118.002397
40. DeWitt ES, Chandler SF, Hylind RJ, Beausejour Ladouceur V, Blume JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J.* (2015) 36:847–55. doi: 10.1093/eurheartj/ehu509
41. Verhagen JMA, Hodgkinson KA, Haywood AF, Connors S, French VM, Merner ND, et al. Genetic evaluation of cardiomyopathy-a heart failure society of America Practice Guideline. *J Card Fail.* (2018) 24:281–302. doi: 10.1016/j.cardfail.2018.03.004
42. James CA, Syrris P, van Tintelen JP, Calkins H. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. *Eur Heart J.* (2020) 41:1393–400. doi: 10.1093/eurheartj/ehaa141
43. Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EW, Houlston RS, Clift S, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmpotlar keratoderma and woolly hair (Naxos disease) maps to 17q21. *Circulation.* (1998) 97:2049–58. doi: 10.1161/01.CIR.97.20.2049
44. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiovascular disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. *Cardiovasc Pathol.* (2004) 13:185–94. doi: 10.1016/j.carpath.2003.04.009
45. Norrett EE, Hatsell SJ, Carvajal-Huerta L, Cabzbas JC, Common J, Purkis PE, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. *Hum Mol Genet.* (2000) 9:2761–6. doi: 10.1093/hmg/1.8.2761
46. Kaplan SR, Gard JJ, Carvajal-Huerta L, Ruiz-Cabezás JC, Thiene G, Saffitz JE. Structural and molecular pathology of the heart in Carvajal syndrome. *Cardiovase Pathol.* (2004) 13:26–32. doi: 10.1016/S1054-8807(03)00107-8
47. Hammill WW, Fyde DA, Gillette PC, Taylor A, Dobson RL, Thompson RP. Cardiomyopathy with arrhythmias and ectodermal dysplasia: a previously unreported association. *Am Heart J.* (1988) 115:373–7. doi: 10.1016/0002-8703(88)90484-X
48. Protonotarios N, Tsatsopoulou A, Anastasakis A, Sevdalis E, McKoy G, Stratos K, et al. Gene-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. *Am J Cardiol.* (2001) 38:1477– 84. doi: 10.1016/S0001-509X(01)02568-6
49. Narin N, Akcakus M, Gunes T, Celiker A, Baykan A, Uzum K, et al. Arrhythmogenic right ventricular cardiomyopathy (Naxos disease): report of a Turkish family. *Pacing Clin Electrophysiol.* (2003) 26:2326– 9. doi: 10.1111/j.1540-8159.2003.00370.x
50. Protonotarios N, Tsatsopoulou A. Naxos disease: cardiovascular syndrome due to cell adhesion defect. *Orphanet J Rare Dis.* (2006) 1:4. doi: 10.1186/1750-1172-1-4
51. Polivka L, Bodemer C, Hadji-Rabia S. Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases. *J Med Genet.* (2016) 53:289– 95. doi: 10.1136/jmedgenet-2015-103403
52. Maruthappu T, Posafalvi A, Castelletti S, Delaney PJ, Syrris P, O’Toole EA, et al. Loss-of-function desmoplakin I and II mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. *Br J Dermatol.* (2019) 180:1114–22. doi: 10.1111/bjd.17388
53. Pigors M, Schwierger-Briel A, Cosgrea R, Diaconeasa A, Bruckner-Tuderman L, Fleck T, et al. Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiovascular disease. *Acta Derm Venereol.* (2015) 95:337–40. doi: 10.2340/00015555-1974
54. Chalabreysse L, Senni F, Bruyere P, Aimé B, Ollagnier C, Bozieo A, et al. A new hypoligamentous syndrome: Carvajal/Naxos syndrome secondary to desmoplakin dominant mutations. *J Dent Res.* (2011) 90:58– 64. doi: 10.1177/0022034510383984
55. Alcalai R, Metzger S, Rosenheck S, Meiner V, Chajek-Shaul T. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia,
skin disorder, and woolly hair. *J Am Coll Cardiol.* (2003) 43:319–27. doi: 10.1016/S0735-1097(03)00628-4
66. Jonkman MF, Pasmooj AM, Pasmans SG, van den Berg MP, Ter Horst HJ, Timmer A, et al. Loss of desmolakin tail causes lethal anacantholytic epidermolysis bullosa. *Am J Hum Genet.* (2005) 77:653–60. doi: 10.1086/469901
67. Hobbs RP, Han SY, van der Zwaag PA, Bolling MC, Jongbloed JD, Jonkman MF, et al. Insights from a desmolakin mutation identified in lethal anacantholytic epidermolysis bullosa. *Invest Dermatol.* (2010) 130:2680–3. doi: 10.1038/jid.2010.189
68. Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). *Heart Rhythm.* (2004) 1:3–11. doi: 10.1016/j.hrthm.2004.01.001
69. Mavrogeni S, Protonotarios N, Tsatsopoulou A, Papachristou P, Sendroukari E, Papadopoulos G. Naxos disease evolution mimicking acute myocarditis: the role of cardiovascular magnetic resonance imaging. *Int J Cardiol.* (2013) 166:e14–15. doi: 10.1016/j.ijcard.2012.12.078
70. Uzumcu A, Norgett EE, Dindar A, Uyguner O, Nisli K, Kayserili H, et al. Loss of desmolakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. *J Med Genet.* (2006) 43:e5. doi: 10.1136/jmg.2005.032904
71. Sen-Chowdhry S, McWenna WJ. When rare illuminates common: how cardiocutaneous syndromes transformed our perspective on arrhythmogenic cardiomyopathy. *Cell Commun Adhes.* (2014) 21:3–11. doi: 10.1007/s00417-013-0674-5
72. Phillips B, Madhavan S, James CA, Tichnell C, Murray B, Needleman E, et al. Approach to family screening in arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations. *Circulation.* (2013) 105:253–26. doi: 10.1161/CIRCRESAHA.109.201418
73. Cerrone M, Noorma L, Lin X, Chikourko H, Liang FX, van der Nagel R, et al. Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. *Cardiovasc Res.* (2012) 95:460–9. doi: 10.1093/cvr/cvs218
74. Cerrone M, Lin X, Zhang M, Aguillo-Pascual E, Pfenninger A, Chikourko Gusk H, et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. *Circulation.* (2014) 129:1092–103. doi: 10.1161/CIRCULATIONAHA.113.003077
75. Cerrone M, Montnach J, Lin X, Zhao YT, Zhang M, Aguillo-Pascual E, et al. Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm. *Nat Commun.* (2017) 8:1006. doi: 10.1038/s41467-017-00127-0
76. Bauce B, Rampazzo A, Basso C, Mazzotti E, Rigato I, Steriotis A, et al. Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations. *Heart Rhythm.* (2011) 8:1686–95. doi: 10.1016/j.hrthm.2011.06.026
77. Sabel KG, Blomström-Lundqvist C, Olsson SB, Enestrom S, Arrhythmogenic right ventricular dysplasia in brother and sister: is it related to myocarditis? *Pediatr Cardiol.* (1990) 11:113–6. doi: 10.1007/BF02239576
78. Pinamonti B, Delmar M, et al. Plakophilin-2 Truncation Variants in Patients Clinically and pathogenic desmosomal mutations in index-patients predict outcome of family screening. *J Am Coll Cardiol.* (2019) 74:755–63. doi: 10.1016/j.jacc.2019.04.044
79. Pinamonti B, Dragos AM, Pyzaras SA, Merlo M, Pivetta A, Barbati G, et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. *Eur Heart J.* (2011) 32:1105–13. doi: 10.1093/eurheartj/ehr040
80. Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorma L, Bhuian YA, et al. Arrhythmogenic right ventricular dysplasia/cardio myopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening. *J Cardiovasc Med.* (2019) 2:293–50. doi: 10.1161/CIRCGEN.120.003020
81. Vreeker A, van Stuijvenberg L, Hund TJ, Mohler PJ, Nikkels PG, van Veen TA. Assembly of the cardiac intercalated disk during pre- and postnatal development of the human heart. *PLoS ONE.* (2014) 9:e94722. doi: 10.1371/journal.pone.0094722
82. Bhuian YA, Te Riele AS, James CA, Bhounse A, Sawant AC, Groeneweg JA, James CA, Murray B, et al. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. *Heart Rhythm.* (2017) 14:883–91. doi: 10.1016/j.hrthm.2017.02.013
83. Mast TP, James CA, Calkins H, Teske AJ, Tichnell C, Murray B, et al. Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *JAMA Cardiol.* (2017) 2:293–302. doi: 10.1001/jamacardio.2016.3034
84. Porzu A, Rigato I, Pilchou K, Perazzolo Marra M, Migliore F, Mazzotti E, et al. Phenotypic expression is a prerequisite for malignant arrhythmic events and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy. *Europace.* (2016) 18:1086–94. doi: 10.1093/europace/euv205
85. James CA, Bhounse A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiacinopathy-associated desmosomal mutation carriers. *J Am Coll Cardiol.* (2013) 62:1290–7. doi: 10.1016/j.jacc.2013.06.033
86. Ruwald AC, Marcus F, Estes NA 3rd, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J.* (2015) 36:1735–1743. doi: 10.1093/eurheartj/ehv110
97. Gupta R, Tichnell C, Murray B, Rizzo S, Te Riele A, Tandri H, et al. Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Am J Cardiol. (2017) 120:117–7. doi: 10.1016/j.amjcard.2017.03.251

98. Lie OH, Dejaard LA, Saberniak J, Rootwell C, Stokke MK, Edvardsen T, et al. Harmful effects of exercise intensity and exercise duration in patients with arrhythmogenic cardiomyopathy. JACC Clin Electrophysiol. (2018) 4:744–53. doi: 10.1016/j.jacep.2018.01.010

99. Lie OH, Chivulescu M, Rootwell-Norberg C, Ribe M, Bogsrud MP, Lyseggen E, et al. Left ventricular dysfunction in arrhythmogenic cardiomyopathy: association with exercise exposure, genetic basis, and prognosis. J Am Heart Assoc. (2021) 10:e018680. doi: 10.1161/JAHA.120.018680

100. Sawant AC, Bhonsale A, te Riele AS, Tichnell C, Murray B, Russell SD, et al. Exercise has a disproportional role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. (2014) 3:e001471. doi: 10.1161/JAHA.114.001471

101. Wang W, Orgeron G, Tichnell C, Murray BA, Agafonova J, Cadrin-Tourigny J, Chelko S, Paulin, F. L., Hodgkinson KA, MacLaughlan S, Stuckless SN, Templeton R. Role of exercise restriction is protective for genotype-positive family members with arrhythmogenic right ventricular cardiomyopathy. J Am Heart Assoc. (2018) 7:e008843. doi: 10.1161/JAHA.118.008843

102. Zorzi A, Cipriani A, Bariani R, Pilichou K, Corda Rados D, Balse B. Role of exercise as a modulating factor in arrhythmogenic cardiomyopathy. Circ Cardiol Rep. (2021) 23:57. doi: 10.1007/s1886-021-01489-0

103. Paulin, F. L., Hodgkinson KA, MacLaughlan S, Stuckless SN, Templeton C, Shah S, et al. Exercise and arrhythmogenic cardiomyopathy. JACC Clin Electrophysiol. (2014) 7:590–7. doi: 10.1016/CIRCEP.113.001224

104. Fabritz L, Hoogendijk MG, Sclicuna BP, van Amersfoorth SC, Fortuermier L, Wolf S, et al. Effect of reducing right ventricular arrhythmogenic cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol. (2011) 57:740–50. doi: 10.1016/j.jacc.2010.09.046

105. Kalantarian S, Vittinghoff E, Klein L, Scheiman MM. Effect of preload reducing therapy on right ventricular size and function in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. (2021) 18:1186–91. doi: 10.1016/j.hrthm.2021.03.018

106. Wichter T, Borgere H, Haverkamp W, Chen X, Brethard G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. (1992) 86:29–37. doi: 10.1161/01.CI.R.86.1.29

107. Marcus GM, Gilnden DV, Polonovsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. (2009) 54:609–15. doi: 10.1016/j.jacc.2009.04.052

108. Ernmark S, Gerstenfeld EP, Svetlichnya Y, Scheiman MM. Use of flecanide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. (2017) 14:564–9. doi: 10.1016/j.hrthm.2016.12.010

109. Phillips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia-cardiomyopathy. Circ Arrhythm Electrophysiol. (2012) 5:499–505. doi: 10.1161/CIRCEP.111.968677

110. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. (2009) 120:366–75. doi: 10.1161/CIRCULATIONAHA.108.834903

111. Daiemee UA, Assis FR, Murray B, Tichnell C, James CA, Calkins H, et al. Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy: Insights from the Johns Hopkins ARVC Program. Heart Rhythm. (2021) 18:1369–76. doi: 10.1016/j.hrthm.2021.04.028

112. Bai R, Di Biase L, Shkvarka K, Mohanty P, Tung R, Santangelo P, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardio-myopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol. (2011) 4:478–85. doi: 10.1161/CIRCEP.111.963066

113. Haqqani HM, Tschabrunn CM, Betensky BP, Lavi N, Tzou WS, Zado ES, et al. Layered activation of epicardial scar in arrhythmogenic right ventricular dysplasia: possible substrate for confined epicardial circuits. Circ Arrhythm Electrophysiol. (2012). 5:796–803. doi: 10.1161/CIRCEP.111.967935

114. Bosman LP, Sammani A, James CA, Cadrin-Tourigny J, Calkins H, Van Tintel JP, et al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm. (2018) 15:1097–107. doi: 10.1016/j.hrthm.2018.01.031

115. Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. (2015) 132:441–53. doi: 10.1161/CIRCULATIONAHA.115.017944

116. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol. (2018) 72:e91–e220. doi: 10.1016/j.jacc.2017.10.053

117. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Comparison of different prediction models for the indication of implanted cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy. ESC Heart Fail. (2020) 7:4080–8. doi: 10.1002/ehf2.13019

118. Casella M, Gasperetti A, Gaertano F, Busana M, Sommariva E, Catto V, et al. Long-term follow-up analysis of a highly characterized arrhythmogenic cardiomyopathy cohort with classical and non-classical phenotypes—a real-world assessment of a novel prediction model: does the subtype really matter. Europace. (2020) 22:797–805. doi: 10.1093/europace/euz352

119. Gasperetti A, Russo AD, Busana M, Dessanai M, Pizzamiglio F, Sagner AM, et al. Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. (2020) 17:1251–9. doi: 10.1016/j.hrthm.2020.03.007

Conflict of Interest: HC receives research support from Boston Scientific Corp. CJ receives salary support from this investigator initiated research grant from Boston Scientific Corp. HC is a consultant for Medtronic Inc., Biosense Webster, Pfizer Inc., and Abbott. CJ is a consultant for Pfizer.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 te Riele, James, Calkins and Tsatsopoulou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.